H. Möller

发表

Neuroleptic associated extrapyramidal symptoms.

S. Zierz, F. Jerusalem, I. Maurer, 1995, The British journal of psychiatry : the journal of mental science.

Clomipramine challenge test in obsessive-compulsive disorder: an indicator for altered serotonergic activity/neuroendocrine responsivity?

M. Rao, S. Kasper, G. Höflich, 1994, European Neuropsychopharmacology.

Hypericum in the Treatment of Seasonal Affective Disorders

S. Kasper, S. Ruhrmann, B. Martinez, 1994, Journal of geriatric psychiatry and neurology.

Pharmacogenetics – genomics and personalized psychiatry

D. Rujescu, H. Möller, 2010, European Psychiatry.

C.12.03 Evidence of agomelatine's antidepressant efficacy: the key points

H. Möller, 2007, European Neuropsychopharmacology.

Antidepressant efficacy in relation to item analysis and severity of depression: a placebo‐controlled trial of fluvoxamine versus imipramine

H. Möller, S. Kasper, S. Montgomery, 1995, International clinical psychopharmacology.

Efficacy of New Generation Antidepressants: Meta-Analysis of Imipramine-Controlled Studies

H. Möller, S. Kasper, J. Fuger, 1994, Pharmacopsychiatry.

Effects of Acamprosate on Psychomotor Performance and Driving Ability in Abstinent Alcoholics

U. Preuss, M. Soyka, H J Möller, 1998, Pharmacopsychiatry.

Epidemiological Evidence for a Low Abuse Potential of Zolpidem

H. Möller, R. Bottlender, M. Soyka, 2000, Pharmacopsychiatry.

Long‐term treatment of chronic schizophrenia with risperidone: an open‐label? multicenter study of 386 patients

H. Möller, L. Knorring, D. Addington, 1998, International clinical psychopharmacology.

Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone

H. Möller, A. Puech, J. Peuskens, 2002, European Neuropsychopharmacology.

Low plasma thyroid indices of depressed patients are attenuated by antidepressant drugs and influence treatment outcome.

H. Möller, S. Kasper, S. Ruhrmann, 1996, Pharmacopsychiatry.

Low Serum Levels of Tricyclic Antidepressants in Amitriptyline- and Doxepin-Treated Inpatients with Depressive Syndromes are Associated with Nonresponse

H. Möller, G. Laux, M. Rao, 1996, Pharmacopsychiatry.

Clinical Response to Sleep Deprivation and Auditory-Evoked Potentials - Preliminary Results

P. Danos, J. Kaiser, S. Ruhrmann, 1994, Pharmacopsychiatry.

Brofaromine - a Selective, Reversible, and Short-Acting MAO-A Inhibitor: Review of the Pharmacological and Clinical Findings

P. Waldmeier, G. Wendt, H. Möller, 1991, Pharmacopsychiatry.

Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder

H. Möller, S. Kasper, S. Ruhrmann, 1998, Psychological Medicine.

Amisulpride: a review of its efficacyin schizophrenia

H. Möller, H. Möller, 2000, Acta psychiatrica Scandinavica. Supplementum.

Placebo-Controlled Trial of the Xanthine Derivative Propentofylline in Dementia

H. Möller, B. Saletu, I. Maurer, 1994, Pharmacopsychiatry.

Pharmacogenetics – genomics and personalized psychiatry

H. Möller, Dan Rujescu, D. Rujescu, 2010, European Psychiatry.

Brofaromine in elderly major depressed patients — a comparative trial versus imipramine

H. Möller, H. Volz, H. Möller, 1993, European Neuropsychopharmacology.

Long-term studies of antipsychotic drugs in schizophrenia — discussion

H. Möller, 1996, European Psychiatry.

Brofaromine in Non-endogenous Major Depressed Inpatients - Results of a Preliminary Dose-finding Trial VersusTranylcypromine1

H. Heimann, J. Bellaire, H. Möller, 1994, Pharmacopsychiatry.

Zolpidem Dependence in a Patient with Former Polysubstance Abuse

M. Soyka, C. Schütz, H. Möller, 1997, Pharmacopsychiatry.

D2-Dopamine Receptor Occupancy measured by IBZM-SPECT in Relation to Extrapyramidal Side Effects

H. Möller, S. Kasper, K. Broich, 1998, Pharmacopsychiatry.